Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive early data for Lilly and Sankyo anti-clotting drug
In a phase Ib study, greater than 90% of prasugrel-treated patients achieved greater than 20% inhibition of platelet aggregation, compared with less than 50% of Plavix treated patients.
In a phase Ib study, greater than 90% of prasugrel-treated patients achieved greater than 20% inhibition of platelet aggregation, compared with less than 50% of Plavix treated patients.
Coreg CR is the controlled release formulation of the already marketed Coreg. The new formulation was developed with Flamel Technologies’ micropump technology and is designed to control dissolution
The new process, described in the journal BioTechniques, involves an new method of intravenously injecting DNA into animals, whose immune systems respond by producing antibodies that can be
The company said in a statement that it is undertaking an evaluation of these issues and that significant safety concerns have been identified in the trial to date.
The transaction includes an initial payment of $5 million in cash and the issuance of 11.5 million shares of Pharmos common stock for a combined value of approximately
In November 2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix has utilized its proprietary human fat cell based technologies for discovering compounds that reduce
Data showed that treatment with Chrysalin (TP508) in the 503 participants did not relate to a statistically significant benefit compared to placebo in the primary efficacy endpoint, a
Targeted enrollment will be expanded from 74 to 330 patients. The expanded phase II/III trial will include additional study sites outside the US. In order to support the
In May 2002, ActivX and Kyorin entered into a collaboration for the discovery and development of new drugs for the treatment of type 2 diabetes. The companies’ joint
Based on findings in rats, researchers believe this drug has the potential to be an effective treatment for inherited amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease).